Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults

Next Previous
X
Search
Trial Profile

An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PH 109 (Primary)
  • Indications Hypertrophic scars
  • Focus Therapeutic Use
  • Sponsors Phio Pharmaceuticals

    • Most Recent Events

    • 21 Feb 2018 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
    • 18 Dec 2017 Results presented in an RXi Pharmaceuticals media release.
    • 18 Dec 2017 According to an RXi Pharmaceuticals media release, Joseph P. Hunstad is the principal investigator for the Company's Dermatology Clinical Program with RXI-109.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top